Research Evidence Anecdotal Efficacy Side Effects Price Dosing & Protocol Peptide Deep Dive Regulatory Safety Notes

Thymosin Alpha-1

Thymosin Alpha-1 has Phase 2 RCT-grade evidence for COVID-19. Off-label / exploratory data exists for 45 additional indications (Non-small Cell Lung Cancer; HIV-associated lipodystrophy). 4 trials were withdrawn or terminated — surfaced below as signal of absence, not omitted.

Research Evidence

Evidence shape

Depthhow much

55 registered trials

19 completed · 1 with posted results · 16 recruiting / active · combined n=189

Breadthhow many areas

50 indications mapped

1 with results · 45 thin / exploratory · 1 animal-only · 43 single-trial long-tail

Qualityhow rigorous

Highest tier: Phase 3

12 distinct sponsors · AE table from NCT04428008 · 26 linked publications on registered trials

Breadth and depth78 rows captured

Human

direct clinical signal

55

Animal

translational support

11

In vitro

mechanistic support

12

HighMediumLow

Anecdotal efficacy

Immune support & strengthening

8 linked reports sit in this bucket. The captured signal currently skews positive, with 75% positive, 12.5% mixed, and 12.5% negative.

1-4 of 8

+“In my case it was prescribed by my doctor, shipped to me from a pharmacy, and self administered once a day for a month(I noticed a change after literally one dose).”r/boulder · 2 upvotes +“Positive: no negative side effects occured, Thymosin seemed to decrease stress Level during sleep”r/LongCovidTrials · 1 upvotes +“Lost 5.5lbs of inflammation since starting 11/16, feel so much relief all over.”r/Peptides_for_Women · 2 upvotes +“it is dropping my hs-crp and esr, but not my tpo”r/Hashimotos · 1 upvotes

Side effects

Clinical research side effects

Anecdotal side effects

Side effect source data

38 linked sources are available across clinical rows and community reports.

Clinical 30Anecdotal 8

1-4 of 38

ClinicalOther

COVID-19 — 5.5%NCT04428008 · Active Arm (n=91) · placebo arm: 7.1% (7/98)

ClinicalOther

Sepsis — 4.4%NCT04428008 · Active Arm (n=91) · placebo arm: 0.0% (0/98)

ClinicalOther

Respiratory failure — 4.4%NCT04428008 · Active Arm (n=91) · placebo arm: 2.0% (2/98)

ClinicalOther

COVID-negative pneumonia — 4.4%NCT04428008 · Active Arm (n=91) · placebo arm: 1.0% (1/98)

Price

1

Natty Peptides

2400 mg

$57.20

$0.027/mg

2

Nextgen Peptides

500 mg

$100.00

$0.2/mg

3

Swiss Chems

500 mg

$579.95

$1.16/mg

4

High Purity Peptides

100 mg

$150.00

$1.5/mg

5

Genpeptide

10 mg

$35.00

$3.5/mg

6

Peptide Titans

100 mg

$389.99

$3.9/mg

price offers can be sorted by column

1-6 of 98

Dosing & Protocol

How Thymosin Alpha-1 is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials

Published clinical-trial protocols · n = 19

Typical dose

No quantified dose captured for this tier.

Timing: unspecified
Cycle: unspecified

19 completed trials identified; trial dosing not reliably extracted from registry data.

8 sources

Clinician practice

Doctor & published-protocol guidance · n = 2

Typical dose

1.6 mg

1.6 mg
1.6 mg

Frequency: daily
Timing: unspecified
Route: subQ
Cycle: unspecified

Clinician protocols dose 1.6 mg daily subQ (2 sources).

2 sources

Anecdotal

Community-reported real-world use · n = 8

Typical dose

No quantified dose captured for this tier.

No structured protocol details captured for this tier yet.

Community reports primarily highlight its use for immune support and strengthening. Out of 8 reports, 75% were positive, 12.5% mixed, and 12.5% negative concerning outcomes.

Dose & protocol sources

10 linked sources are available across the research, clinician, and community tiers. Each card states what that source says, with a link to it.

Research trials 8Clinician practice 2Anecdotal 0

Research trialsNCT04428008

Number of Participants With COVID-19 Infection

NCT04428008 · Phase 2 ↗

Research trialsNCT03659578

Incidence of ≥grade 2 radiation pneumonitis (CTCAE 5.0 version)

NCT03659578 · Phase 2 ↗

Research trialsNCT04963712

Change in CD4+T cell counts

NCT04963712 · Early Phase 1 ↗

Research trialsNCT00001036

Completed; results not posted

NCT00001036 · Phase 1 ↗

Research trialsNCT02867267

28-day all-cause mortality

NCT02867267 · Phase 3 ↗

Research trialsNCT02883595

Ta 1 improving immune function of monocyte for sepsis, used by flow cytometric to measure phagocytosis(CD11b, CD64), antigen presenting(HLA-DR, CD86 and PD-L1), and apoptosis(active caspase 3) on monocyte,

NCT02883595 · Phase 4 ↗

Research trialsNCT01943617

Decompensated rate of Liver Cirrhosis after 2 years treatment

NCT01943617 · Phase 4 ↗

Research trialsNCT01938820

Regression of HBV-induced liver cirrhosis

NCT01938820 · Phase 4 ↗

Clinician practicePeptide Dosing Protocols

Dose 1.6 mgFrequency dailyRoute subQCycle 6-12 months

Peptide Dosing Protocols — Garret Grant (peptidedosingprotocols.com) ↗

Clinician practiceInternational Peptide Society monograph

IPS monograph exists but is members-only; awaiting authenticated session cookie.

International Peptide Society monograph (members-only) ↗

Peptide Deep Dive

Peptide Deep Dive is not projected for this peptide yet.

Peptide feedback

0 forum replies

Live community discussion for Thymosin Alpha-1, shown here in the site layout and continued on the TVR forum.

Add feedback

No peptide feedback yet

Start the peptide feedback thread on the TVR forum.